Polar Capital Global Healthcare Trust plc (PCGH) Ordinary 25p Shares
Sell:350.00p
Buy:353.00p
0
Change:
No change
No change
FTSE All Share:0.47%
Market closed |
Prices as at close on 24 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- Create an alert
- This stock can be held in a
Sell:350.00p
Buy:353.00p
Change:
No change
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 24 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:350.00p
Buy:353.00p
Change:
No change
No change
Market closed |
Prices as at close on 24 December 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
HL comment
Objective
The Company’s investment objective is to generate capital growth by investing in a global portfolio of healthcare stocks.The Company seeks to achieve this objective by investing in a diversified global portfolio consisting primarily of listed equities issued by healthcare companies involved in pharmaceuticals, medical services, medical devices and biotechnology. The portfolio is expected to be diversified by factors such as geography, industry sub-sector and investment size.
| Security | Weight |
|---|---|
| Eli Lilly and Co | 8.26% |
| UnitedHealth Group Inc | 7.55% |
| Novo Nordisk DKK0.1 B | 6.01% |
| AbbVie Inc | 5.05% |
| Roche Holdings AG NPV | 4.50% |
| Sandoz Group AG CHF0.05 | 3.53% |
| Sanofi Ordinary Euro 2 | 3.32% |
| Terumo Corp | 3.29% |
| Fresenius SE & Co KGaA NPV | 3.20% |
| Intuitive Surgical Inc | 3.18% |
| Sector | Weight |
|---|---|
| Healthcare | 99.86% |
| Country | Weight |
|---|---|
| United States | 47.39% |
| Switzerland | 12.92% |
| Denmark | 11.41% |
| Japan | 6.25% |
| France | 5.67% |
| Germany | 3.20% |
| Belgium | 3.12% |
| Sweden | 3.07% |
| United Kingdom | 2.37% |
| Italy | 1.91% |
Fee Structure
Management fee is 0.75% p.a. of the lower of the Market Capitalisation and NAV. Performance fee is equal to 10% of the excess total return over benchmark Index plus 1.5% p.a. compounded annually. Agreement terminable not less than 12 months written notice.
Dividend Policy
The Company focus remains on capital growth, and the dividend will be paid bi-annually in February and August. The policy may result in lower dividends being paid than historically to recognise the focus on capital growth.
ASSET SPLIT
Trust Manager
James Douglas
Manager Bio
James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma. James received a PhD and first class honours degree in Medicinal Chemistry from Newcastle University. Further to this, James also holds an ACCA diploma in financial management.
Board Of Directors
Lisa ArnoldChairman, Jeremy Whitley, Neal Ransome
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.